Research programme: bone morphogenetic protein receptor agonists - Thrasos Therapeutics

Drug Profile

Research programme: bone morphogenetic protein receptor agonists - Thrasos Therapeutics

Alternative Names: AA 123; AA 166; AA 204; THR 575; THR-123; THR-166; THR-C; THR-V-123

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Thrasos Therapeutics
  • Class Peptides; Small molecules
  • Mechanism of Action Bone morphogenetic protein receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Kidney disorders

Highest Development Phases

  • No development reported Breast cancer; Cartilage disorders; Kidney disorders; Obesity; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Kidney-disorders in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Kidney-disorders(Prevention) in USA
  • 04 Nov 2017 No recent reports of development identified for research development in Breast-cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top